FDA advisory on nevirapine.
The FDA summarized existing warnings against ongoing nevirapine treatment in women with a CD4 count over 250, due to a greatly increased risk of serious liver toxicity. (The warnings do not apply to single-dose nevirapine, which does not cause this problem.)
D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage* / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine